Protection of Rabbits from Viral Challenge by Gene Gun-Based Intracutaneous Vaccination with a Combination of Cottontail Rabbit Papillomavirus E1, E2, E6, and E7 Genes

RICAI HAN,1 NANCY M. CLADEL,1 CYNTHIA A. REED,1 XUWEN PENG,2 AND NEIL D. CHRISTENSEN1,3*

Jake Gittlen Cancer Research Institute, Department of Pathology,1 Department of Comparative Medicine,2 and Department of Microbiology and Immunology,3 Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033

Received 4 February 1999/Accepted 12 May 1999

In this study, cottontail rabbit papillomavirus infection of domestic rabbits was used as an animal model to develop papillomavirus early gene-based vaccines. Groups of rabbits were intracutaneously vaccinated with single papillomavirus early genes E1, E2, E6, and E7 or with a combination of these four genes. Only a fraction of rabbits were protected from subsequent viral challenge when vaccinated with the E1 or E6 gene. Viral tumor growth in those rabbits vaccinated with the E1 or E2 gene was suppressed compared to that in controls. In contrast, seven of nine rabbits vaccinated with the combination of the E1, E2, E6, and E7 genes were completely protected against viral challenge. These data indicated that intracutaneous genetic vaccination with the combination of the E1, E2, E6, and E7 genes can be an effective strategy for immunoprophylaxis of papillomavirus infection.

Human papillomavirus (HPV) infection induces mucosal and/or cutaneous hyperproliferative lesions which persist for months or years. Certain HPV types are linked to the development of skin cancer (21), tumors of the head and neck (8), and anogenital carcinomas (30). Development and testing of papillomavirus vaccines have been conducted extensively in animal models, such as bovine papillomavirus (BPV) infection of cattle (3) and cottontail rabbit papillomavirus (CRPV) infection of domestic rabbits (16). Currently, several strategies have been utilized to develop papillomavirus vaccines. One strategy involves the induction of neutralizing antibodies by immunization with the viral structural protein L1 or L2, particularly, virus-like particles (VLPs) assembled from L1 or L1/L2. Another strategy involves the induction of cell-mediated immunity by papillomavirus early gene/protein-based vaccination. Recently, VLPs containing L1 and chimeric molecules of L1 and early proteins were used as immunogens. This strategy has been applied to elicit concurrent viral neutralizing antibodies and cell-mediated immunity specific for viral early proteins (11).

A number of studies have demonstrated that VLP immunization protected animals against experimental virus challenge in the CRPV-infected rabbit model (2, 6, 13), in the BPV-infected cow model (15), and in the canine oral papillomavirus (COPV)-infected beagle dog model (28). Furthermore, genetic vaccination with CRPV L1 (9, 26) or immunization with CRPV L1 proteins expressed as bacterial fusion proteins (18) also protected rabbits from viral challenge. Protection has also been achieved by immunization with L2 proteins (5, 10, 19). One caveat of these animal model systems is that protection from natural papillomavirus infection has not been determined. In experimental infection models, sites to be infected are vigorously scarified or wounded, resulting in damage to local blood vessels and the release of circulating neutralizing antibodies at the sites of infection. In contrast, natural infection may occur following microtrauma to the epithelium without significant damage to blood vessels and subsequent direct exposure of virus to circulating neutralizing antibodies. Thus, circulating neutralizing antibodies may be unable to protect against natural papillomavirus infection. Protective vaccines targeting virus-infected epithelium via cell-mediated immunity would overcome these potential limitations.

Induction of protective cell-mediated immunity by immunization with papillomavirus early gene/proteins is expected to prevent the establishment of new lesions (immunoprophylaxis) as well as to eliminate existing lesions (immunotherapy). However, early studies disclosed variable results. In the CRPV-infected rabbit model, different papillomavirus early antigens and several methods of antigen delivery have been applied in an attempt to elicit protective antipapillomavirus immunity: (i) immunization with bacterial fusion proteins of CRPV E1 and/or E2 (24); (ii) immunization with recombinant Listeria monocytogenes expressing CRPV E1 (14); (iii) intracutaneous genetic vaccination of rabbits with CRPV E6 (27); and (iv) intramuscular injection of plasmid DNA encoding CRPV E1, E2, E6, or E7 (12). The immunity so induced stimulated papilloma regression in a fraction of vaccinated rabbits (14, 24) and partially protected rabbits from subsequent virus challenge (27). However, none of these studies revealed complete protection. In the BPV-infected cow model, immunization with BPV E6 and E7 proteins delayed papilloma formation, reduced papilloma size, and promoted papilloma regression but also did not lead to complete protection (3, 4). BPV E2 immunizations were ineffective (4). In the present study, we immunized rabbits by gene gun-mediated intracutaneous vaccination with individual CRPV E1, E2, E6, and E7 genes or with a combination of all four genes. We report that vaccination with the combination of CRPV E1, E2, E6, and E7 genes provided strong and complete protection of outbred rabbits against CRPV challenge.
Preparation of DNA vectors and gene gun-mediated immunization. CRPV E1, E2, E6, and E7 DNA genes were amplified by PCR and cloned into V1Ins expression vector (generous gift of M. A. Liu, Merck & Co, Westpoint, Pa.) at the BgII site individually (20). The resultant recombinant plasmids were referred to as V1JnsE1, V1JnsE2, V1JnsE6, and V1JnsE7, respectively. Plasmid DNA was precipitated onto 1.6-μm-diameter gold microparticles at a ratio of 1 μg of DNA/0.5 mg of gold particles as described by the manufacturer (Bio-Rad, Hercules, Calif.). Outbred New Zealand White rabbits (Covance Gold Products Inc., Denver, Pa.) were immunized by gene gun-mediated intracutaneous delivery of DNA/gold particles onto dorsal skin sites at 400 lb/in².

Protection of rabbits against challenge with cloned CRPV viral DNA. In our laboratory, we currently use a CRPV stock which was obtained originally from cottontail rabbit viral papillomas and then expanded by using the nude mouse xenograft system. It is possible that several CRPV variants exist in this virus stock (23). In this study, the E1, E2, E6, and E7 genes were cloned from a single clone or a variant. Theoretically, immunity to these early proteins will generate protection against the matching CRPV variant but not to other variants if critical epitopes are antigenically unrelated. Rabbits were thus challenged with the same cloned viral DNA (17) from which the E1, E2, E6, and E7 genes were amplified. In the first experiment, 24 rabbits were divided into six groups (Table 1). For the groups vaccinated with a single gene or vector, rabbits received three immunizations at 3-week intervals: 20 μg of DNA for each of the first and the second immunizations, and 10 μg of DNA for the final booster immunization. For the group vaccinated with the combination of the four genes, rabbits received only two immunizations at 3-week intervals, 10 μg of each E1-, E2-, E6-, and E7-encoding plasmid DNA. Numbers of challenged sites in each rabbit that produced papillomas were shown in Table 1. Papillomas grew at all challenged sites in all five control rabbits. All control rabbits grew papillomas at virion-challenged sites, and all protected rabbits were resistant to the viral challenge except one rabbit which was vaccinated with the E1 gene alone. Papillomas on the latter rabbit appeared at 4 weeks after virus challenge and persisted without regression until the termination of this experiment (4 months). Vaccination with the combination of E1, E2, E6, and E7 genes therefore completely protected rabbits from virus particle infection.

Papilloma growth in nonprotected and partially protected rabbits. Papilloma size was measured for a total of 14 weeks following viral DNA challenge in those nonprotected and partially protected rabbits. Mean papilloma sizes per site for rabbits vaccinated with the E1 or E2 genes were significantly smaller than those in the vector-injected rabbits (vector group versus E1 group, t test, P < 0.05; vector group versus E2 group, t test, P < 0.05). Papilloma size per site for E6-vaccinated rabbits was somewhat smaller than that for vector-vaccinated control rabbits, but size differences were not statistically significant at 14 weeks postchallenge with virus (Fig. 1). E7 vaccination has little effect on papilloma growth rates (Fig. 1).

Systemic regression of papillomas was observed only for two rabbits that were vaccinated with the combination of the E1, E2, E6, and E7 genes in the first experiment (rabbits 1 and 2). For one partially protected rabbit in the E2 group (rabbit 1; Table 1), papillomas at one challenged site rapidly regressed and papilloma growth at another site was significantly suppressed (9 mm² at 14 weeks) but did not regress. One papil-

**TABLE 1. Papilloma growth in vaccinated and control rabbits**

<table>
<thead>
<tr>
<th>Group</th>
<th>1st dose (μg)</th>
<th>2nd dose (μg)</th>
<th>3rd dose (μg)</th>
<th>No. of sites with papillomas</th>
<th>% Sites with papillomas</th>
</tr>
</thead>
<tbody>
<tr>
<td>First expt</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>V1JnsE1</td>
<td>20</td>
<td>20</td>
<td>10</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>V1JnsE2</td>
<td>20</td>
<td>20</td>
<td>10</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>V1JnsE6</td>
<td>20</td>
<td>20</td>
<td>10</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>V1JnsE7</td>
<td>20</td>
<td>20</td>
<td>20</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>Combined</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Vector</td>
<td>20</td>
<td>20</td>
<td>10</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Second expt</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Combined</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Vector</td>
<td>10</td>
<td>10</td>
<td>6</td>
<td>4</td>
<td>4</td>
</tr>
</tbody>
</table>

a Rabbıts in each group were vaccinated with one type of plasmid DNA, as indicated, except that rabbits in the combined group were vaccinated with four genes, V1JnsE1, V1JnsE2, V1JnsE6, and V1JnsE7. b R1 through R5 denote rabbit numbers in each group. R5 was not used in the first experiment. c Papillomas regressed in 3 weeks. d ND, not done.
loma on one E6-vaccinated rabbit (rabbit 3; Table 1) appeared at week 4, then regressed, and reappeared at week 8. However, this papilloma regressed again, regrew at 14 weeks, and then became persistent. These observations indicated that immunity induced by single gene vaccinations by using the protocol described for the first experiment had an impact on papilloma growth but was insufficient to completely eliminate all viral papillomas. It is possible that additional booster vaccinations with single genes prior to viral DNA challenge may have led to an increased level of protection.

**T-cell-mediated immune responses.** In vitro peripheral blood mononuclear cell (PBMC) proliferation assays were conducted to evaluate T-cell-mediated immune responses (12). PBMCs were isolated from ear arterial blood one week after the final booster immunization and stimulated with the specific antigens, CRPV E1, E2, E6 and E7, as histidine-tagged fusion proteins. Control antigens for all rabbits were CRPV L2 histidine-tagged fusion proteins. All fusion proteins were prepared by using recombinant baculoviruses and purified by using nickel columns under denaturing conditions (Invitrogen, San Diego, Calif.) as previously described (12). All four E2-vaccinated rabbits showed strong antigen-specific proliferative responses (Table 2). Three of four rabbits in each of the E1, E6, and E7 groups also showed antigen-specific proliferative responses (Table 2). These data indicated that genetic vaccination with CRPV E1, E2, E6, and E7 genes induced T-cell-mediated immunity. Interestingly, in vitro antigen-specific proliferative responses were strongest in the E2- and E7-vaccinated rabbits despite a lack of protection against viral DNA challenge in these two groups (Table 2). Furthermore, papilloma sizes in rabbits vaccinated with E7 were substantially larger than the papillomas of the E6-vaccinated group (Fig. 1). These data suggest that in vitro antigen-specific proliferative responses do not correlate with in vivo protective immunity.

**Humoral immune responses.** Rabbit serum was collected before vaccination and after the first, second, and third vaccinations (Fig. 1). Western blot analysis did not detect specific anti-E1, -E2, -E6, or -E7 antibodies in those vaccinated rabbits (Fig. 1). The presence of anti-E6 antibodies was confirmed by the absence of papillomas of the E6-vaccinated group (Fig. 1). These data indicated that genetic vaccination with CRPV E1, E2, E6 and E7, as histidine-tagged fusion proteins, CRPV E1, E2, E6 and E7 genes induced T-cell-mediated immune responses. In vitro peripheral blood mononuclear cell (PBMC) proliferation assays were conducted to evaluate T-cell-mediated immune responses (12). PBMCs were isolated from ear arterial blood one week after the final booster immunization and stimulated with the specific antigens, CRPV E1, E2, E6 and E7, as histidine-tagged fusion proteins. All fusion proteins were prepared by using recombinant baculoviruses and purified by using nickel columns under denaturing conditions (Invitrogen, San Diego, Calif.) as previously described (12). All four E2-vaccinated rabbits showed strong antigen-specific proliferative responses (Table 2). Three of four rabbits in each of the E1, E6, and E7 groups also showed antigen-specific proliferative responses (Table 2). These data indicated that genetic vaccination with CRPV E1, E2, E6, and E7 genes induced T-cell-mediated immunity. Interestingly, in vitro antigen-specific proliferative responses were strongest in the E2- and E7-vaccinated rabbits despite a lack of protection against viral DNA challenge in these two groups (Table 2). Furthermore, papilloma sizes in rabbits vaccinated with E7 were substantially larger than the papillomas of the E6-vaccinated group (Fig. 1). These data suggest that in vitro antigen-specific proliferative responses do not correlate with in vivo protective immunity.

**Humoral immune responses.** Rabbit serum was collected before vaccination and after the first, second, and third vaccinations (Fig. 1). Western blot analysis did not detect specific anti-E1, -E2, -E6, or -E7 antibodies in those vaccinated rabbits (data not shown).

Papillomavirus-induced lesions are maintained by hyperproliferation of virus-infected, undifferentiated cells in the basal and suprabasal layers of the epithelium. Immune-mediated

![FIG. 1. Papilloma growth for nonprotected and control rabbits in the first experiment. Data represent the means ± standard errors of the means of papilloma areas that were calculated from the total numbers of papillomas, which are indicated in parentheses, for each group. Individual papilloma size was calculated by multiplying length (millimeters) and width (millimeters). Mean papilloma areas were significantly different in the V1Jns group and V1JnsE1 group (t test, P < 0.05) and in the V1Jns group and V1Jns group and V1JnsE2 group (t test, P < 0.05) but not in the V1Jns group and V1JnsE6 and in the V1Jns group and V1JnsE7 group at 14 weeks postchallenge.](http://jvi.asm.org/)
cure of papillomavirus-induced lesions can be successful only when the latter cells are eliminated by effector cells, such as cytotoxic T lymphocytes. A potential vaccine candidate gene/protein(s) therefore must be expressed in the infected, undifferentiated cells and, in addition, must be immunogenic. Experimental evidence for the viral proteins E1, E2, E6, and E7 in basal and suprabasal layers of infected epithelium has been indirectly established by RNA-RNA in situ hybridization studies (1, 25, 29). These four genes therefore are potential candidate vaccines. In the present study, E1 was the most effective of the four early genes for protection by vaccination of animals against viral challenge. These results are consistent with the findings of Jensen and coworkers (14). Immunization with the E6 gene only provided partial protection. A similar result was obtained by other investigators (27). Unexpectedly, T-cell-mediated immune responses for the E2 immunization group were directly established by RNA-RNA in situ hybridization studies (1, 25, 29). These four genes therefore are potential candidates. In the present study, E1 was the most effective gene for protection by vaccination of animals with a full-length, nondenatured product. J. Virol. 74:945–953.

REFERENCES


